HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use CORLANOR® safely and effectively. See full prescribing information for CORLANOR.

CORLANOR (ivabradine) tablets, for oral use
Initial U.S. Approval: 2015

INDICATIONS AND USAGE
Corlanor (ivabradine) is a hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated to reduce the risk of hospitalization for worsening heart failure in patients with stable, symptomatic chronic heart failure with left ventricular ejection fraction ≤ 35%, who are in sinus rhythm with resting heart rate ≥ 70 beats per minute and either are on maximally tolerated doses of beta-blockers or have a contraindication to beta-blocker use. (1)

DOSAGE AND ADMINISTRATION
• Starting dose is 5 mg twice daily. After 2 weeks of treatment, adjust dose based on heart rate. The maximum dose is 7.5 mg twice daily. (2)
• In patients with conduction defects or in whom bradycardia could lead to hemodynamic compromise, initiate dosing at 2.5 mg twice daily. (2)

DOSE FORMS AND STRENGTHS
Tablets: 5 mg, 7.5 mg (3)

CONTRAINDICATIONS
• Acute decompensated heart failure (4)
• Blood pressure less than 90/50 mmHg (4)
• Sick sinus syndrome, sinoatrial block or 3rd degree AV block, unless a functioning demand pacemaker is present (4)
• Resting heart rate less than 60 bpm prior to treatment (4)
• Severe hepatic impairment (4)
• Pacemaker dependence (heart rate maintained exclusively by the pacemaker) (4)

WARNINGS AND PRECAUTIONS
• Fetal toxicity: Females should use effective contraception. (5.1)
• Monitor patients for atrial fibrillation. (5.2)
• Monitor heart rate decreases and bradycardia symptoms during treatment. (5.3)

ADVERSE REACTIONS
Most common adverse reactions occurring in ≥ 1% of patients are bradycardia, hypertension, atrial fibrillation and luminous phenomena (phosphenes). (6)

DRUG INTERACTIONS
• CYP3A4 inhibitors increase Corlanor plasma concentrations and CYP3A4 inducers decrease Corlanor plasma concentrations. (7.1)
• Negative chronotropes: Increased risk of bradycardia, monitor heart rate. (7.2)

USE IN SPECIFIC POPULATIONS
• Lactation: Breastfeeding not recommended. (8.2)

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.

Revised: 04/2015

FULL PRESCRIBING INFORMATION: CONTENTS*
1. INDICATIONS AND USAGE
2. DOSAGE AND ADMINISTRATION
3. DOSAGE FORMS AND STRENGTHS
4. CONTRAINDICATIONS
5. WARNINGS AND PRECAUTIONS
   5.1 Fetal Toxicity
   5.2 Atrial Fibrillation
   5.3 Bradycardia and Conduction Disturbances
6. ADVERSE REACTIONS
   6.1 Clinical Trials Experience
   6.2 Postmarketing Experience
7. DRUG INTERACTIONS
   7.1 Cytochrome P450-Based Interactions
   7.2 Negative Chronotropes
   7.3 Pacemakers
8. USE IN SPECIFIC POPULATIONS
   8.1 Pregnancy
   8.2 Lactation
   8.3 Females and Males of Reproductive Potential
   8.4 Pediatric Use
   8.5 Geriatric Use
   8.6 Hepatic Impairment
   8.7 Renal Impairment
10. OVERDOSAGE
11. DESCRIPTION
12. CLINICAL PHARMACOLOGY
   12.1 Mechanism of Action
   12.2 Pharmacodynamics
   12.3 Pharmacokinetics
13. NONCLINICAL TOXICOLOGY
   13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
   13.2 Animal Toxicology and/or Pharmacology
14. CLINICAL STUDIES
16. HOW SUPPLIED/STORAGE AND HANDLING
17. PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.
FULL PRESCRIBING INFORMATION

1. INDICATIONS AND USAGE
Corlanor is indicated to reduce the risk of hospitalization for worsening heart failure in patients with stable, symptomatic chronic heart failure with left ventricular ejection fraction ≤ 35%, who are in sinus rhythm with resting heart rate ≥ 70 beats per minute and either are on maximally tolerated doses of beta-blockers or have a contraindication to beta-blocker use.

2. DOSAGE AND ADMINISTRATION
The recommended starting dose of Corlanor is 5 mg twice daily with meals. Assess patient after two weeks and adjust dose to achieve a resting heart rate between 50 and 60 beats per minute (bpm) as shown in Table 1. Thereafter, adjust dose as needed based on resting heart rate and tolerability. The maximum dose is 7.5 mg twice daily.

In patients with a history of conduction defects, or other patients in whom bradycardia could lead to hemodynamic compromise, initiate therapy at 2.5 mg twice daily before increasing the dose based on heart rate [see Warnings and Precautions (5.3)].

Table 1. Dose Adjustment

<table>
<thead>
<tr>
<th>Heart Rate</th>
<th>Dose Adjustment</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt; 60 bpm</td>
<td>Increase dose by 2.5 mg (given twice daily) up to a maximum dose of 7.5 mg twice daily</td>
</tr>
<tr>
<td>50-60 bpm</td>
<td>Maintain dose</td>
</tr>
<tr>
<td>&lt; 50 bpm or signs and symptoms of bradycardia</td>
<td>Decrease dose by 2.5 mg (given twice daily); if current dose is 2.5 mg twice daily, discontinue therapy*</td>
</tr>
</tbody>
</table>

*[see Warnings and Precautions (5.3).]*

3. DOSAGE FORMS AND STRENGTHS
Corlanor 5 mg: salmon-colored, oval-shaped, film-coated tablet, scored on both edges, debossed with “5” on one face and bisected on the other face. The tablet is scored and can be divided into equal halves to provide a 2.5 mg dose.

Corlanor 7.5 mg: salmon-colored, triangular-shaped, film-coated tablet debossed with “7.5” on one face and plain on the other face.
4. CONTRAINDICATIONS

Corlanor is contraindicated in patients with:

- Acute decompensated heart failure
- Blood pressure less than 90/50 mmHg
- Sick sinus syndrome, sinoatrial block, or 3rd degree AV block, unless a functioning demand pacemaker is present
- Resting heart rate less than 60 bpm prior to treatment [see Warnings and Precautions (5.3)]
- Severe hepatic impairment [see Use in Specific Populations (8.6)]
- Pacemaker dependence (heart rate maintained exclusively by the pacemaker) [see Drug Interactions (7.3)]
- Concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors [see Drug Interactions (7.1)]

5. WARNINGS AND PRECAUTIONS

5.1 Fetal Toxicity

Corlanor may cause fetal toxicity when administered to a pregnant woman based on findings in animal studies. Embryo-fetal toxicity and cardiac teratogenic effects were observed in fetuses of pregnant rats treated during organogenesis at exposures 1 to 3 times the human exposures (AUC_{0-24hr}) at the maximum recommended human dose (MRHD) [see Use in Specific Populations (8.1)]. Advise females to use effective contraception when taking Corlanor [see Use in Specific Populations (8.3)].

5.2 Atrial Fibrillation

Corlanor increases the risk of atrial fibrillation. In SHIFT, the rate of atrial fibrillation was 5.0% per patient-year in patients treated with Corlanor and 3.9% per patient-year in patients treated with placebo [see Clinical Studies (14)]. Regularly monitor cardiac rhythm. Discontinue Corlanor if atrial fibrillation develops.

5.3 Bradycardia and Conduction Disturbances

Bradycardia, sinus arrest, and heart block have occurred with Corlanor. The rate of bradycardia was 6.0% per patient-year in patients treated with Corlanor (2.7% symptomatic; 3.4% asymptomatic) and 1.3% per patient-year in patients treated with placebo. Risk factors for bradycardia include sinus node dysfunction, conduction defects (e.g., 1st or 2nd degree atrioventricular block, bundle branch block), ventricular dyssynchrony, and use of other negative chronotropes (e.g., digoxin, diltiazem, verapamil, amiodarone). Concurrent use of verapamil or diltiazem will increase Corlanor exposure, may themselves contribute to heart rate lowering, and should be avoided [see Clinical Pharmacology (12.3)]. Avoid use of Corlanor in
patients with 2nd degree atrioventricular block, unless a functioning demand pacemaker is present [see Contraindications (4) and Dosage and Administration (2)].

6. ADVERSE REACTIONS

Clinically significant adverse reactions that appear in other sections of the labeling include:

- Fetal Toxicity [see Warnings and Precautions (5.1)]
- Atrial Fibrillation [see Warnings and Precautions (5.2)]
- Bradycardia and Conduction Disturbances [see Warnings and Precautions (5.3)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In the Systolic Heart failure treatment with the $I_f$ inhibitor ivabradine Trial (SHIFT), safety was evaluated in 3260 patients treated with Corlanor and 3278 patients given placebo. The median duration of Corlanor exposure was 21.5 months.

The most common adverse drug reactions in the SHIFT trial are shown in Table 2 [see also Warnings and Precautions (5.2), (5.3)].

Table 2. Adverse Drug Reactions with Rates ≥ 1.0% Higher on Ivabradine than Placebo occurring in > 1% on Ivabradine in SHIFT

<table>
<thead>
<tr>
<th></th>
<th>Ivabradine N=3260</th>
<th>Placebo N=3278</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bradycardia</td>
<td>10%</td>
<td>2.2%</td>
</tr>
<tr>
<td>Hypertension, blood pressure increased</td>
<td>8.9%</td>
<td>7.8%</td>
</tr>
<tr>
<td>Atrial fibrillation</td>
<td>8.3%</td>
<td>6.6%</td>
</tr>
<tr>
<td>Phosphenes, visual brightness</td>
<td>2.8%</td>
<td>0.5%</td>
</tr>
</tbody>
</table>
Luminous Phenomena (Phosphenes)
Phosphenes are phenomena described as a transiently enhanced brightness in a limited area of the visual field, halos, image decomposition (stroboscopic or kaleidoscopic effects), colored bright lights, or multiple images (retinal persistency). Phosphenes are usually triggered by sudden variations in light intensity. Corlanor can cause phosphenes, thought to be mediated through Corlanor’s effects on retinal photoreceptors [see Clinical Pharmacology (12.1)]. Onset is generally within the first 2 months of treatment, after which they may occur repeatedly. Phosphenes were generally reported to be of mild to moderate intensity and led to treatment discontinuation in < 1% of patients; most resolved during or after treatment.

6.2 Postmarketing Experience
Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or establish a causal relationship to drug exposure.

The following adverse reactions have been identified during post-approval use of Corlanor: syncope, hypotension, angioedema, erythema, rash, pruritus, urticaria, vertigo, diplopia, and visual impairment.

7. DRUG INTERACTIONS
7.1 Cytochrome P450-Based Interactions
Corlanor is primarily metabolized by CYP3A4. Concomitant use of CYP3A4 inhibitors increases ivabradine plasma concentrations, and use of CYP3A4 inducers decreases them. Increased plasma concentrations may exacerbate bradycardia and conduction disturbances.

The concomitant use of strong CYP3A4 inhibitors is contraindicated [see Contraindications (4) and Clinical Pharmacology (12.3)]. Examples of strong CYP3A4 inhibitors include azole antifungals (e.g., itraconazole), macrolide antibiotics (e.g., clarithromycin, telithromycin), HIV protease inhibitors (e.g., nelfinavir), and nefazodone.

Avoid concomitant use of moderate CYP3A4 inhibitors when using Corlanor. Examples of moderate CYP3A4 inhibitors include diltiazem, verapamil, and grapefruit juice [see Warnings and Precautions (5.3) and Clinical Pharmacology (12.3)].

Avoid concomitant use of CYP3A4 inducers when using Corlanor. Examples of CYP3A4 inducers include St. John’s wort, rifampicin, barbiturates, and phenytoin [see Clinical Pharmacology (12.3)].
7.2 Negative Chronotropes
Most patients receiving Corlanor will also be treated with a beta-blocker. The risk of bradycardia increases with concomitant administration of drugs that slow heart rate (e.g., digoxin, amiodarone, beta-blockers). Monitor heart rate in patients taking Corlanor with other negative chronotropes.

7.3 Pacemakers
Corlanor dosing is based on heart rate reduction, targeting a heart rate of 50 to 60 beats per minute [see Dosage and Administration (2)]. Patients with demand pacemakers set to a rate \( \geq 60 \) beats per minute cannot achieve a target heart rate < 60 beats per minute, and these patients were excluded from clinical trials [see Clinical Studies (14)]. The use of Corlanor is not recommended in patients with demand pacemakers set to rates \( \geq 60 \) beats per minute.

8. USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
Risk Summary
Based on findings in animals, Corlanor may cause fetal harm when administered to a pregnant woman. There are no adequate and well-controlled studies of Corlanor in pregnant women to inform any drug-associated risks. In animal reproduction studies, oral administration of ivabradine to pregnant rats during organogenesis at a dosage providing 1 to 3 times the human exposure (AUC0-24hr) at the MRHD resulted in embryo-fetal toxicity and teratogenicity manifested as abnormal shape of the heart, interventricular septal defect, and complex anomalies of primary arteries. Increased postnatal mortality was associated with these teratogenic effects in rats. In pregnant rabbits, increased post-implantation loss was noted at an exposure (AUC0-24hr) 5 times the human exposure at the MRHD. Lower doses were not tested in rabbits. The background risk of major birth defects for the indicated population is unknown. The estimated background risk of major birth defects in the U.S. general population is 2 to 4%, however, and the estimated risk of miscarriage is 15 to 20% in clinically recognized pregnancies. Advise a pregnant woman of the potential risk to the fetus.

Clinical Considerations
Disease-associated maternal and/or embryo/fetal risk
Stroke volume and heart rate increase during pregnancy, increasing cardiac output, especially during the first trimester. Pregnant patients with left ventricular ejection fraction less than 35% on maximally tolerated doses of beta-blockers may be particularly heart-rate dependent for augmenting cardiac output. Therefore, pregnant patients who are started on Corlanor, especially during the first trimester, should be
followed closely for destabilization of their congestive heart failure that could result from heart rate slowing.

Monitor pregnant women with chronic heart failure in 3rd trimester of pregnancy for preterm birth.

**Data**

*Animal Data*

In pregnant rats, oral administration of ivabradine during the period of organogenesis (gestation day 6-15) at doses of 2.3, 4.6, 9.3, or 19 mg/kg/day resulted in fetal toxicity and teratogenic effects. Increased intrauterine and post-natal mortality and cardiac malformations were observed at doses $\geq 2.3$ mg/kg/day (equivalent to the human exposure at the MRHD based on $\text{AUC}_{0-24\text{hr}}$). Teratogenic effects including interventricular septal defect and complex anomalies of major arteries were observed at doses $\geq 4.6$ mg/kg/day (approximately 3 times the human exposure at the MRHD based on $\text{AUC}_{0-24\text{hr}}$).

In pregnant rabbits, oral administration of ivabradine during the period of organogenesis (gestation day 6-18) at doses of 7, 14, or 28 mg/kg/day resulted in fetal toxicity and teratogenicity. Treatment with all doses $\geq 7$ mg/kg/day (equivalent to the human exposure at the MRHD based on $\text{AUC}_{0-24\text{hr}}$) caused an increase in post-implantation loss. At the high dose of 28 mg/kg/day (approximately 15 times the human exposure at the MRHD based on $\text{AUC}_{0-24\text{hr}}$), reduced fetal and placental weights were observed, and evidence of teratogenicity (ectrodactylia observed in 2 of 148 fetuses from 2 of 18 litters) was demonstrated.

In the pre- and postnatal study, pregnant rats received oral administration of ivabradine at doses of 2.5, 7, or 20 mg/kg/day from gestation day 6 to lactation day 20. Increased postnatal mortality associated with cardiac teratogenic findings was observed in the F1 pups delivered by dams treated at the high dose (approximately 15 times the human exposure at the MRHD based on $\text{AUC}_{0-24\text{hr}}$).

**8.2 Lactation**

*Risk Summary*

There is no information regarding the presence of ivabradine in human milk, the effects of ivabradine on the breastfed infant, or the effects of the drug on milk production. Animal studies have shown, however, that ivabradine is present in rat milk [see Data]. Because of the potential risk to breastfed infants from exposure to Corlanor, breastfeeding is not recommended.
Data
Lactating rats received daily oral doses of $^{14}$C-ivabradine (7 mg/kg) on post-parturition days 10 to 14; milk and maternal plasma were collected at 0.5 and 2.5 hours post-dose on day 14. The ratios of total radioactivity associated with $^{14}$C-ivabradine or its metabolites in milk vs. plasma were 1.5 and 1.8, respectively, indicating that ivabradine is transferred to milk after oral administration.

8.3 Females and Males of Reproductive Potential

Contraception

Females
Corlanor may cause fetal harm, based on animal data. Advise females of reproductive potential to use effective contraception during Corlanor treatment [see Use in Specific Populations (8.1)].

8.4 Pediatric Use
Safety and effectiveness in pediatric patients have not been established.

8.5 Geriatric Use
No pharmacokinetic differences have been observed in elderly (≥ 65 years) or very elderly (≥ 75 years) patients compared to the overall population. However, Corlanor has only been studied in a limited number of patients ≥ 75 years of age.

8.6 Hepatic Impairment
No dose adjustment is required in patients with mild or moderate hepatic impairment. Corlanor is contraindicated in patients with severe hepatic impairment (Child-Pugh C) as it has not been studied in this population and an increase in systemic exposure is anticipated [see Contraindications (4) and Clinical Pharmacology (12.3)].

8.7 Renal Impairment
No dosage adjustment is required for patients with creatinine clearance 15 to 60 mL/min. No data are available for patients with creatinine clearance below 15 mL/min [see Clinical Pharmacology (12.3)].

10. OVERDOSAGE
Overdose may lead to severe and prolonged bradycardia. In the event of bradycardia with poor hemodynamic tolerance, temporary cardiac pacing may be required. Supportive treatment, including intravenous (IV) fluids, atropine, and intravenous beta-stimulating agents such as isoproterenol, may be considered.
11. DESCRIPTION

Corlanor (ivabradine) is a hyperpolarization-activated cyclic nucleotide-gated channel blocker that reduces the spontaneous pacemaker activity of the cardiac sinus node by selectively inhibiting the If current ($I_f$), resulting in heart rate reduction with no effect on ventricular repolarization and no effects on myocardial contractility.

The chemical name for ivabradine is 3-((3-3,4-Dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl)methyl) methyl amino) propyl)-1,3,4,5-tetrahydro-7,8-dimethoxy-2H-3-benzazepin-2-one, hydrochloride. The molecular formula is $C_{27}H_{36}N_2O_5$, HCl, and the molecular weight (free base + HCl) is 505.1 (468.6 + 36.5). The chemical structure of ivabradine is shown in Figure 1.

Figure 1. Chemical Structure of Ivabradine

Corlanor tablets are formulated as salmon-colored, film-coated tablets for oral administration in strengths of 5 mg and 7.5 mg of ivabradine as the free base equivalent.

Inactive Ingredients

Core
Lactose monohydrate, maize starch, maltodextrin, magnesium stearate, colloidal silicon dioxide

Film Coating
Hypromellose, titanium dioxide, glycerol, magnesium stearate, polyethylene glycol 6000, yellow iron oxide, red iron oxide

12. CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Corlanor blocks the hyperpolarization-activated cyclic nucleotide-gated (HCN) channel responsible for the cardiac pacemaker $I_f$-current, which regulates heart rate. In clinical electrophysiology studies, the cardiac effects were most pronounced in the sinoatrial (SA) node, but prolongation of the AH interval has
occurred on the surface ECG, as has PR interval prolongation. There was no effect on ventricular repolarization and no effects on myocardial contractility [see Clinical Pharmacology (12.2)].

Corlanor can also inhibit the retinal current $I_h$. $I_h$ is involved in curtailing retinal responses to bright light stimuli. Under triggering circumstances (e.g., rapid changes in luminosity), partial inhibition of $I_h$ by Corlanor may underlie the luminous phenomena experienced by patients. Luminous phenomena (phosphenes) are described as a transient enhanced brightness in a limited area of the visual field [see Adverse Reactions (6.1)].

12.2 Pharmacodynamics
Corlanor causes a dose-dependent reduction in heart rate. The size of the effect is dependent on the baseline heart rate (i.e., greater heart rate reduction occurs in subjects with higher baseline heart rate). At recommended doses, heart rate reduction is approximately 10 bpm at rest and during exercise. Analysis of heart rate reduction vs. dose indicates a plateau effect at doses > 20 mg twice daily. In a study of subjects with preexisting conduction system disease (first- or second-degree AV block or left or right bundle branch block) requiring electrophysiologic study, IV ivabradine (0.20 mg/kg) administration slowed the overall heart rate by approximately 15 bpm, increased the PR interval (29 msec), and increased the AH interval (27 msec).

Corlanor does not have negative inotropic effects. Ivabradine increases the uncorrected QT interval with heart rate slowing but does not cause rate-corrected prolongation of QT.

12.3 Pharmacokinetics
Absorption and Bioavailability
Following oral administration, peak plasma ivabradine concentrations are reached in approximately 1 hour under fasting conditions. The absolute oral bioavailability of ivabradine is approximately 40% because of first-pass elimination in the gut and liver.

Food delays absorption by approximately 1 hour and increases plasma exposure by 20% to 40%. Corlanor should be taken with meals [see Dosage and Administration (2)].

Ivabradine is approximately 70% plasma protein bound, and the volume of distribution at steady state is approximately 100 L.
**Metabolism and Excretion**

The pharmacokinetics of ivabradine are linear over an oral dose range of 0.5 mg to 24 mg. Ivabradine is extensively metabolized in the liver and intestines by CYP3A4-mediated oxidation. The major metabolite is the N-desmethylated derivative (S 18982), which is equipotent to ivabradine and circulates at concentrations approximately 40% that of ivabradine. The N-desmethylated derivative is also metabolized by CYP3A4. Ivabradine plasma levels decline with a distribution half-life of 2 hours and an effective half-life of approximately 6 hours.

The total clearance of ivabradine is 24 L/h, and renal clearance is approximately 4.2 L/h, with ~4% of an oral dose excreted unchanged in urine. The excretion of metabolites occurs to a similar extent via feces and urine.

**Drug Interactions**

The effects of coadministered drugs (CYP3A4 inhibitors, substrates, inducers, and other concomitantly administered drugs) on the pharmacokinetics of Corlanor were studied in several single- and multiple-dose studies. Pharmacokinetic measures indicating the magnitude of these interactions are presented in Figure 2.
Digoxin exposure did not change when concomitantly administered with ivabradine. No dose adjustment is required when ivabradine is concomitantly administered with digoxin.

**Effect of Ivabradine on Metformin Pharmacokinetics**

Ivabradine, dosed at 10 mg twice daily to steady state, did not affect the pharmacokinetics of metformin (an organic cation transporter [OCT2] sensitive substrate). The geometric mean (90% confidence interval [CI]) ratios of \( C_{\text{max}} \) and \( \text{AUC}_{\text{inf}} \) of metformin, with and without ivabradine were 0.98 [0.83–1.15] and 1.02 [0.86–1.22], respectively. No dose adjustment is required for metformin when administered with Corlanor.

**Specific Populations**

**Age**

No pharmacokinetic differences (AUC or \( C_{\text{max}} \)) have been observed between elderly (\( \geq 65 \) years) or very elderly (\( \geq 75 \) years) patients and the overall patient population [see Use in Specific Populations (8.5)].
**Hepatic Impairment**

In patients with mild (Child-Pugh A) and moderate (Child-Pugh B) hepatic impairment, the pharmacokinetics of Corlanor were similar to that in patients with normal hepatic function. No data are available in patients with severe hepatic impairment (Child-Pugh C) [see Contraindications (4)].

**Renal Impairment**

Renal impairment (creatinine clearance from 15 to 60 mL/min) has minimal effect on the pharmacokinetics of Corlanor. No data are available for patients with creatinine clearance below 15 mL/min.

**Pediatrics**

The pharmacokinetics of Corlanor have not been investigated in patients < 18 years of age.

### 13. NONCLINICAL TOXICOLOGY

#### 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

There was no evidence of carcinogenicity when mice and rats received ivabradine up to 104 weeks by dietary administration. High doses in these studies were associated with mean ivabradine exposures of at least 37 times higher than the human exposure (AUC$_{0-24hr}$) at the MRHD.

Ivabradine tested negative in the following assays: bacterial reverse mutation (Ames) assay, *in vivo* bone marrow micronucleus assay in both mouse and rat, *in vivo* chromosomal aberration assay in rats, and *in vivo* unscheduled DNA synthesis assay in rats. Results of the *in vitro* chromosomal aberration assay were equivocal at concentrations approximately 1,500 times the human C$_{max}$ at the MRHD. Ivabradine tested positive in the mouse lymphoma assays and *in vitro* unscheduled DNA synthesis assay in rat hepatocytes at concentrations greater than 1,500 times the human C$_{max}$ at the MRHD.

Reproduction toxicity studies in animals demonstrated that ivabradine did not affect fertility in male or female rats at exposures 46 to 133 times the human exposure (AUC$_{0-24hr}$) at the MRHD.

#### 13.2 Animal Toxicology and/or Pharmacology

Reversible changes in retinal function were observed in dogs administered oral ivabradine at total doses of 2, 7, or 24 mg/kg/day (approximately 0.6 to 50 times the human exposure at the MRHD based on AUC$_{0-24hr}$) for 52 weeks. Retinal function assessed by electroretinography demonstrated reductions in cone system responses, which reversed within a week post-dosing, and were not associated with damage to ocular structures as evaluated by light microscopy. These data are consistent with the pharmacological
effect of ivabradine related to its interaction with hyperpolarization-activated $I_h$ currents in the retina, which share homology with the cardiac pacemaker $I_f$ current.

14. CLINICAL STUDIES

SHIFT

The Systolic Heart failure treatment with the $I_f$ inhibitor ivabradine Trial (SHIFT) was a randomized, double-blind trial comparing Corlanor and placebo in 6558 adult patients with stable NYHA class II to IV heart failure, left ventricular ejection fraction $\leq$ 35%, and resting heart rate $\geq$ 70 bpm. Patients had to have been clinically stable for at least 4 weeks on an optimized and stable clinical regimen, which included maximally tolerated doses of beta-blockers and, in most cases, ACE inhibitors or ARBs, spironolactone, and diuretics, with fluid retention and symptoms of congestion minimized. Patients had to have been hospitalized for heart failure within 12 months prior to study entry.

The underlying cause of CHF was coronary artery disease in 68% of patients. At baseline, approximately 49% of randomized subjects were NYHA class II, 50% were NYHA class III, and 2% were NYHA class IV. The mean left ventricular ejection fraction was 29%. All subjects were initiated on Corlanor 5 mg (or matching placebo) twice daily and the dose was increased to 7.5 mg twice daily or decreased to 2.5 mg twice daily to maintain the resting heart rate between 50 and 60 bpm, as tolerated. The primary endpoint was a composite of the first occurrence of either hospitalization for worsening heart failure or cardiovascular death.

Most patients (89%) were taking beta-blockers, with 26% on guideline-defined target daily doses. The main reasons for not receiving the target beta-blocker doses at baseline were hypotension (45% of patients not at target), fatigue (32%), dyspnea (14%), dizziness (12%), history of cardiac decompensation (9%), and bradycardia (6%). For the 11% of patients not receiving any beta-blocker at baseline, the main reasons were chronic obstructive pulmonary disease, hypotension, and asthma. Most patients were also taking ACE inhibitors and/or angiotensin II antagonists (91%), diuretics (83%), and anti-aldosterone agents (60%). Few patients had an implantable cardioverter-defibrillator (ICD) (3.2%) or a cardiac resynchronization therapy (CRT) device (1.1%). Median follow-up was 22.9 months. At 1 month, 63%, 26%, and 8% of Corlanor-treated patients were taking 7.5, 5, and 2.5 mg BID, whereas 3% had withdrawn from the drug, primarily for bradycardia.

SHIFT demonstrated that Corlanor reduced the risk of the combined endpoint of hospitalization for worsening heart failure or cardiovascular death based on a time-to-event analysis (hazard ratio: 0.82, 95% confidence interval [CI]: 0.75, 0.90, $p < 0.0001$) (Table 3). The treatment effect reflected only a reduction
in the risk of hospitalization for worsening heart failure; there was no favorable effect on the mortality component of the primary endpoint. In the overall treatment population, Corlanor had no statistically significant benefit on cardiovascular death.

Table 3. SHIFT – Incidence of the Primary Composite Endpoint and Components

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>Corlanor (N = 3241)</th>
<th>Placebo (N = 3264)</th>
<th>Hazard Ratio [95% CI]</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary composite endpoint: Time to first hospitalization for worsening heart failure or cardiovascular deatha</td>
<td>793 24.5 14.5</td>
<td>937 28.7 17.7</td>
<td>0.82 [0.75, 0.90]</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Hospitalization for worsening heart failure</td>
<td>505 15.6 9.2</td>
<td>660 20.2 12.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiovascular death as first event</td>
<td>288 8.9 4.8</td>
<td>277 8.5 4.7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subjects with events at any time</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hospitalization for worsening heart failureb</td>
<td>514 15.9 9.4</td>
<td>672 20.6 12.7</td>
<td>0.74 [0.66, 0.83]</td>
<td></td>
</tr>
<tr>
<td>Cardiovascular deathb</td>
<td>449 13.9 7.5</td>
<td>491 15.0 8.3</td>
<td>0.91 [0.80, 1.03]</td>
<td></td>
</tr>
</tbody>
</table>

a Subjects who died on the same calendar day as their first hospitalization for worsening heart failure are counted under cardiovascular death.

b Analyses of the components of the primary composite endpoint were not prospectively planned to be adjusted for multiplicity.

N: number of patients at risk; n: number of patients having experienced the endpoint; %: incidence rate = (n/N) x 100; % PY: annual incidence rate = (n/number of patient-years) x 100; CI: confidence interval
The hazard ratio between treatment groups (ivabradine/placebo) was estimated based on an adjusted Cox proportional hazards model with beta-blocker intake at randomization (yes/no) as a covariate; p-value: Wald test

The Kaplan-Meier curve (Figure 3) shows time to first occurrence of the primary composite endpoint of hospitalization for worsening heart failure or cardiovascular death in the overall study.
A wide range of demographic characteristics, baseline disease characteristics, and baseline concomitant medications were examined for their influence on outcomes. Many of these results are shown in Figure 4. Such analyses must be interpreted cautiously, as differences can reflect the play of chance among a large number of analyses.

Most of the results show effects consistent with the overall study result. Corlanor’s benefit on the primary endpoint in SHIFT appeared to decrease as the dose of beta-blockers increased, with little if any benefit demonstrated in patients taking guideline-defined target doses of beta-blockers.
Figure 4. Effect of Treatment on Primary Composite Endpoint in Subgroups

<table>
<thead>
<tr>
<th>% of Total Population</th>
<th>Carfanor n(%)</th>
<th>Placebo n(%)</th>
<th>HR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;65 years</td>
<td>32.0%</td>
<td>295 (23.9%)</td>
<td>410 (32.3%)</td>
</tr>
<tr>
<td>≥75 years</td>
<td>11.1%</td>
<td>145 (17.6%)</td>
<td>227 (25.4%)</td>
</tr>
<tr>
<td>Age quartile</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.8 ≤ age ≤ 55</td>
<td>36.0%</td>
<td>745 (17.6%)</td>
<td>522 (25.4%)</td>
</tr>
<tr>
<td>&gt;55 to ≤ 69</td>
<td>23.1%</td>
<td>617 (25.9%)</td>
<td>597 (24.6%)</td>
</tr>
<tr>
<td>&gt;69</td>
<td>21.3%</td>
<td>673 (30.9%)</td>
<td>458 (25.4%)</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>76.4%</td>
<td>265 (36.6%)</td>
<td>235 (29.3%)</td>
</tr>
<tr>
<td>Female</td>
<td>23.6%</td>
<td>47 (15.9%)</td>
<td>59 (20.7%)</td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Black</td>
<td>8.7%</td>
<td>73 (17.7%)</td>
<td>125 (25.3%)</td>
</tr>
<tr>
<td>Other</td>
<td>9.4%</td>
<td>15 (15.2%)</td>
<td>92 (25.2%)</td>
</tr>
<tr>
<td>Cause of heart failure</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-infarctomic</td>
<td>44.1%</td>
<td>212 (31.9%)</td>
<td>228 (37.9%)</td>
</tr>
<tr>
<td>Infarctomic</td>
<td>55.9%</td>
<td>292 (38.1%)</td>
<td>293 (32.1%)</td>
</tr>
<tr>
<td>Weight quartile</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;59.4</td>
<td>28.9%</td>
<td>626 (37.7%)</td>
<td>725 (28.3%)</td>
</tr>
<tr>
<td>&gt;59.4 to ≤ 79.6</td>
<td>24.0%</td>
<td>493 (22.1%)</td>
<td>593 (26.0%)</td>
</tr>
<tr>
<td>&gt;79.6 to ≤ 91</td>
<td>23.7%</td>
<td>437 (26.9%)</td>
<td>504 (26.7%)</td>
</tr>
<tr>
<td>&gt;91</td>
<td>23.3%</td>
<td>458 (35.2%)</td>
<td>501 (32.7%)</td>
</tr>
<tr>
<td>Baseline heart rate quartile</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤60</td>
<td>20.1%</td>
<td>122 (13.5%)</td>
<td>131 (13.2%)</td>
</tr>
<tr>
<td>60 to ≤ 64</td>
<td>22.1%</td>
<td>158 (21.9%)</td>
<td>163 (21.6%)</td>
</tr>
<tr>
<td>&gt;64</td>
<td>24.0%</td>
<td>166 (23.1%)</td>
<td>183 (26.7%)</td>
</tr>
<tr>
<td>NYHA Class</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NYHA Class II</td>
<td>40.7%</td>
<td>130 (23.2%)</td>
<td>155 (25.3%)</td>
</tr>
<tr>
<td>NYHA Class III</td>
<td>40.5%</td>
<td>129 (23.1%)</td>
<td>155 (26.1%)</td>
</tr>
<tr>
<td>NYHA Class IV</td>
<td>18.8%</td>
<td>66 (26.7%)</td>
<td>55 (28.2%)</td>
</tr>
<tr>
<td>Baseline LV xjection fraction quartile</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤20</td>
<td>27.5%</td>
<td>307 (23.2%)</td>
<td>325 (27.1%)</td>
</tr>
<tr>
<td>&gt;20 to ≤ 30</td>
<td>28.4%</td>
<td>338 (25.4%)</td>
<td>346 (28.9%)</td>
</tr>
<tr>
<td>&gt;30 to ≤ 40</td>
<td>27.0%</td>
<td>338 (25.4%)</td>
<td>346 (28.9%)</td>
</tr>
<tr>
<td>&gt;40</td>
<td>17.1%</td>
<td>86 (16.9%)</td>
<td>96 (20.2%)</td>
</tr>
<tr>
<td>Baseline beta blocker use quartile</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>10.5%</td>
<td>101 (22.4%)</td>
<td>124 (24.3%)</td>
</tr>
<tr>
<td>&gt;0 to ≤ 5</td>
<td>16.5%</td>
<td>143 (29.9%)</td>
<td>171 (32.4%)</td>
</tr>
<tr>
<td>&gt;5 to ≤ 10</td>
<td>20.0%</td>
<td>136 (28.1%)</td>
<td>169 (28.9%)</td>
</tr>
<tr>
<td>&gt;10 to ≤ 30</td>
<td>21.9%</td>
<td>140 (21.1%)</td>
<td>150 (21.0%)</td>
</tr>
<tr>
<td>Baseline aldosterone antagonist use</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>59.7%</td>
<td>355 (25.8%)</td>
<td>333 (23.1%)</td>
</tr>
<tr>
<td>Diabetes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No history of diabetes</td>
<td>52.0%</td>
<td>265 (33.6%)</td>
<td>277 (27.3%)</td>
</tr>
<tr>
<td>History of diabetes</td>
<td>48.0%</td>
<td>237 (31.8%)</td>
<td>224 (27.3%)</td>
</tr>
<tr>
<td>Hypertension</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No history of hypertension</td>
<td>33.7%</td>
<td>203 (25.3%)</td>
<td>207 (27.1%)</td>
</tr>
<tr>
<td>History of hypertension</td>
<td>66.3%</td>
<td>237 (31.8%)</td>
<td>224 (27.3%)</td>
</tr>
<tr>
<td>All</td>
<td>100.0%</td>
<td>793 (34.5%)</td>
<td>937 (38.6%)</td>
</tr>
</tbody>
</table>

Note: The figure above presents effects in various subgroups, all of which are baseline characteristics. The 95% confidence limits that are shown do not take into account the number of comparisons made, and may not reflect the effect of a particular factor after adjustment for all other factors. Apparent homogeneity or heterogeneity among groups should not be over-interpreted.

BEAUTIFUL and SIGNIFY: No benefit in stable coronary artery disease with or without stable heart failure

BEAUTIFUL was a randomized, double-blind, placebo-controlled trial in 10,917 adult patients with coronary artery disease, impaired left ventricular systolic function (ejection fraction < 40%) and resting heart rate ≥ 60 bpm. Patients had stable symptoms of heart failure and/or angina for at least 3 months, and were receiving conventional cardiovascular medications at stable doses for at least 1 month. Beta-blocker therapy was not required, nor was there a protocol mandate to achieve any specific dosing targets for
patients who were taking beta-blockers. Patients were randomized 1:1 to Corlanor or placebo at an initial
dose of 5 mg twice daily with the dose increased to 7.5 mg twice daily depending on resting heart rate and
tolerability. The primary endpoint was the composite of time to first cardiovascular death, hospitalization
for acute myocardial infarction, or hospitalization for new-onset or worsening heart failure. Most patients
were NYHA class II (61.4%) or class III (23.2%) - none were class IV. Through a median follow-up of
19 months, Corlanor did not significantly affect the primary composite endpoint (HR 1.00, 95% CI =
0.91, 1.10).

SIGNIFY was a randomized, double-blind trial administering Corlanor or placebo to 19,102 adult patients
with stable coronary artery disease but without clinically evident heart failure (NYHA class I). Beta-
blocker therapy was not required. Corlanor was initiated at a dose of 7.5 mg twice daily and the dose
could be increased to as high as 10 mg twice daily or down-titrated to 5.0 mg twice daily to achieve a
target heart rate of 55 to 60 bpm. The primary endpoint was a composite of the first occurrence of either
cardiovascular death or myocardial infarction. Through a median follow-up of 24.1 months, Corlanor did
not significantly affect the primary composite endpoint (HR 1.08, 95% CI = 0.96, 1.20).

16. HOW SUPPLIED/STORAGE AND HANDLING
Corlanor 5 mg tablets are formulated as salmon-colored, oval-shaped, film-coated tablets scored on both
edges, marked with “5” on one face and bisected on the other face. They are supplied as follows:
- Bottles of 60 tablets (NDC 55513-800-60)
- Bottles of 180 tablets (NDC 55513-800-80)

Corlanor 7.5 mg tablets are formulated as salmon-colored, triangular-shaped, film-coated tablets debossed
with “7.5” on one face and plain on the other face. They are supplied as follows:
- Bottles of 60 tablets (NDC 55513-810-60)
- Bottles of 180 tablets (NDC 55513-810-80)

Storage
Store at 25°C (77°F); excursions permitted to 15° - 30°C (59° - 86°F) [see USP Controlled Room
Temperature].

17. PATIENT COUNSELING INFORMATION
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
- Fetal Toxicity
  Advise pregnant women of the potential risks to a fetus.
Advise females of reproductive potential to use effective contraception and to notify their healthcare provider with a known or suspected pregnancy [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1, 8.3)].

- **Low Heart Rate**
  Advise patients to report significant decreases in heart rate or symptoms such as dizziness, fatigue, or hypotension [see Warnings and Precautions (5.3)].

- **Atrial fibrillation**
  Advise patients to report symptoms of atrial fibrillation, such as heart palpitations or racing, chest pressure, or worsened shortness of breath [see Warnings and Precautions (5.2)].

- **Phosphenes**
  Advise patients about the possible occurrence of luminous phenomena (phosphenes). Advise patients to use caution if they are driving or using machines in situations where sudden changes in light intensity may occur, especially when driving at night. Advise patients that phosphenes may subside spontaneously during continued treatment with Corlanor [see Adverse Reactions (6.1)].

- **Drug Interactions**
  Advise patients to avoid ingestion of grapefruit juice and St. John’s wort [see Drug Interactions (7.1)].

- **Intake with Food**
  Advise patients to take Corlanor twice daily with meals [see Dosage and Administration (2)].
Each tablet contains 5 mg ivabradine equivalent to 5.39 mg ivabradine as hydrochloride.

Oral Use.

Store at 25°C (77°F), excursions permitted to 15°C - 30°C (59°F - 86°F).

Keep out of the sight and reach of children.

Usual Dose: See package insert for dosage

© YYYY Amgen Inc. All rights reserved.

Patent: http://pat.amgen.com/corlanor/

Manufactured for Amgen Inc.
One Amgen Center Drive
Thousand Oaks, CA 91320-1799

Made in France

Rx Only
Each tablet contains 5 mg ivabradine equivalent to 5.39 mg ivabradine as hydrochloride.

Oral Use.

Store at 25°C (77°F), excursions permitted to 15°C - 30°C (59°F - 86°F).

Keep out of the sight and reach of children.

Usual Dose: See package insert for dosage

© YYYY Amgen Inc. All rights reserved.

Patent: http://pat.amgen.com/corlanor/

Rx Only

Manufactured for Amgen Inc.

One Amgen Center Drive

 Thousand Oaks, CA 91320-1799

 Made in France
Each tablet contains 7.5 mg ivabradine equivalent to 8.085 mg ivabradine as hydrochloride.

Oral Use.

Store at 25°C (77°F), excursions permitted to 15°C - 30°C (59°F - 86°F).

Keep out of the sight and reach of children.
Each tablet contains 7.5 mg ivabradine equivalent to 8.085 mg ivabradine as hydrochloride.

Oral Use.

Store at 25°C (77°F), excursions permitted to 15°C - 30°C (59°F - 86°F).
Keep out of the sight and reach of children.

Usual Dose: See package insert for dosage

© YYYY Amgen Inc. All rights reserved.
Patent: http://pat.amgen.com/corlanor/

Rx Only

Manufactured for Amgen Inc.
One Amgen Center Drive
Thousand Oaks, CA 91320-1799
Made in France
Corlanor®

Each tablet contains 5 mg ivabradine equivalent to 5.39 mg ivabradine as hydrochloride.

Oral Use.
Store at 25°C, excursions permitted to 15°C - 30°C.
Keep out of the sight and reach of children.

Usual Dose: See package insert for dosage

© YYYY Amgen Inc. All rights reserved.
Patent: http://pat.amgen.com/corlanor/
Each tablet contains 5 mg ivabradine equivalent to 5.39 mg ivabradine as hydrochloride.

Oral Use.

Store at 25°C, excursions permitted to 15°C - 30°C.

Keep out of the sight and reach of children.

Usual Dose: See package insert for dosage

© YYYY Amgen Inc. All rights reserved.

Patent: http://pat.amgen.com/corlanor/
Each tablet contains 5 mg ivabradine equivalent to 5.39 mg ivabradine as hydrochloride.

Oral Use.

Store at 25°C, excursions permitted to 15°C - 30°C.

Keep out of the sight and reach of children.
Each tablet contains 7.5 mg ivabradine equivalent to 8.085 mg ivabradine as hydrochloride.
Oral Use.
Store at 25°C, excursions permitted to 15°C - 30°C.
Keep out of the sight and reach of children.
Each tablet contains 7.5 mg ivabradine equivalent to 8.085 mg ivabradine as hydrochloride.

Oral Use.

Store at 25°C, excursions permitted to 15°C - 30°C.

Keep out of the sight and reach of children.
Each tablet contains 7.5 mg ivabradine equivalent to 8.085 mg ivabradine as hydrochloride.

Oral Use.

Store at 25°C, excursions permitted to 15°C - 30°C.

Keep out of the sight and reach of children.

Usual Dose: See package insert for dosage.
Store at 25°C (77°F), excursions permitted to 15°C - 30°C (59°F - 86°F).

Manufactured for Amgen Inc.
One Amgen Center Drive
Thousand Oaks, CA 91320-1799

Rx Only
Store at 25°C (77°F), excursions permitted to 15°C - 30°C (59°F - 86°F).

Manufactured for Amgen Inc.
One Amgen Center Drive
Thousand Oaks, CA 91320-1799

Rx Only
Corlanor®

(i-ih-t-lets)

Store at 25°C (77°F), excursions permitted to 15°C - 30°C (59°F - 86°F).

Manufactured for Amgen Inc.
One Amgen Center Drive
Thousand Oaks, CA 91320-1799

Rx Only
Corlanor® (titlets)

Store at 25°C (77°F), excursions permitted to 15°C - 30°C (59°F - 86°F).

7.5 mg

Manufactured for Amgen Inc.
One Amgen Center Drive
Thousand Oaks, CA 91320-1799

Rx Only